Abstract

Aberrant accumulation of beta-catenin in the cell nucleus as a result of deregulation of the Wnt/beta-catenin pathway is found in various types of cancer. Direct beta-catenin targeting agents are being researched despite obstacles; however, specific beta-catenin drugs for clinical treatments have not been approved so far. We focused on direct beta-catenin targeting of potential therapeutic value as anticancer agents. This review provides recent advances on small molecule beta-catenin agents. Structure-activity relationships and biological activities of reported inhibitors are discussed. This work provides useful knowledge in the discovery of beta-catenin agents.
Lingua originaleEnglish
pagine (da-a)1-15
Numero di pagine15
RivistaMolecules
Volume27
DOI
Stato di pubblicazionePubblicato - 2022

Keywords

  • anticancer agent
  • inhibitor
  • small molecule
  • β-catenin

Fingerprint

Entra nei temi di ricerca di 'Emerging Direct Targeting β-Catenin Agents'. Insieme formano una fingerprint unica.

Cita questo